Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
PR Newswire•02/11/2026•06:30 ET
0
Key Highlights
- ➤ATR 1072 reversed cardiac glycogen accumulation in a PRKAG2 mouse model
- ➤ATR 1072 improved cardiac hypertrophy and ECG parameters in mice
- ➤Corventis Phase 1/2 trial expects initial proof-of-concept data in second-half 2027
- ➤Corventis trial plans enrollment of approximately 37 participants
- ➤Atrium will present the poster November 6 at 5:30 p.m. CT
Expert Statements
Husam Younis, Chief Scientific Officer of Atrium Therapeutics
“Our new nonclinical model reproduced many features of PRKAG2 syndrome, including cardiac glycogen accumulation in the heart.”
Husam Younis, Chief Scientific Officer of Atrium Therapeutics
“We are encouraged to see that a mouse-specific version of ATR 1072 reversed cardiac glycogen accumulation and improved other key features of the disease.”
Husam Younis, Chief Scientific Officer of Atrium Therapeutics
“These findings continue to strengthen the scientific rationale for ATR 1072.”
Husam Younis, Chief Scientific Officer of Atrium Therapeutics
“We now look to the ongoing Phase 1/2 Corventis trial and expect initial proof of concept data in the second half of 2027.”
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 PR Newswire
-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation of cardiac glycogen and cardiac hypertrophy --
Get started
Create a free account to read the full story.